Can-Fite BioPharma (CANF) Income from Continuing Operations (2014 - 2023)
Can-Fite BioPharma's (CANF) quarterly Income from Continuing Operations came in at 28496000.0 in Q4 2023, down 2.89% YoY from 29344713.32 in Q4 2022, and down 1427.94% on a QoQ basis from 1865000.0 in Q3 2023.
Can-Fite BioPharma (CANF) Income from Continuing Operations (2014 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 10 years of Income from Continuing Operations data on file, last reported at 28496000.0 in Q4 2023.
- Quarterly Income from Continuing Operations fell 2.89% year-over-year to 28496000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 35830000.0 (down 3.23% YoY) and the FY2025 annual result came in at 9828000.0, down 24.72% from the prior year.
- Income from Continuing Operations slipped to 28496000.0 in Q4 2023, from 1865000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1572000.0 in Q1 2019 to a low of 28496000.0 in Q4 2023.
- A 5-year average of 5495350.0 and a median of 2734500.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2019 — Income from Continuing Operations tumbled 745.11% — and 2021, when it soared 49.23%.
- Tracing CANF's Income from Continuing Operations over 5 years: stood at 2102000.0 in 2019, then sank by 106.85% to 4348000.0 in 2020, then tumbled by 54.28% to 6708000.0 in 2021, then sank by 312.87% to 27695000.0 in 2022, then fell by 2.89% to 28496000.0 in 2023.
- The last three Income from Continuing Operations figures came in at 28496000.0 (Q4 2023), 1865000.0 (Q3 2023), and 2757000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -28.50 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -2.76 Mn |
| Mar 31, 2023 | -2.71 Mn |
| Dec 31, 2022 | -27.70 Mn |
| Sep 30, 2022 | -2.57 Mn |
| Jun 30, 2022 | -2.07 Mn |
| Mar 31, 2022 | -2.37 Mn |
| Dec 31, 2021 | -6.71 Mn |
| Sep 30, 2021 | -3.40 Mn |
| Jun 30, 2021 | -3.13 Mn |
| Mar 31, 2021 | -2.17 Mn |
| Dec 31, 2020 | -4.35 Mn |
| Sep 30, 2020 | -2.58 Mn |
| Jun 30, 2020 | -3.83 Mn |
| Mar 31, 2020 | -4.28 Mn |
| Dec 31, 2019 | -2.10 Mn |
| Sep 30, 2019 | -2.25 Mn |
| Jun 30, 2019 | -6.15 Mn |
| Mar 31, 2019 | 1.57 Mn |